Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669560 | 0.92 | WNT1 (0.46) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL943948 | 0.88 | GCK (0.41) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL943321 | 0.84 | LTA4H (0.45) | GCK | |
| SCHEMBL945579 | 0.83 | GCK (0.47) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL947020 | 0.83 | MCHR1 (0.49) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL944722 | 0.82 | GCK (0.47) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL944372 | 0.82 | GCK (0.51) | GCKKCNH2NPC1RAB9A | |
| SCHEMBL946413 | 0.82 | GCK (0.49) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL943387 | 0.81 | GCK (0.43) | GCKKCNH2NPC1RAB9AHPGDS | |
| SCHEMBL944042 | 0.81 | GCK (0.46) | GCKKCNH2NPC1RAB9AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2245025-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106209-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009437-A1 | CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES | GLS, GCKR, HK1 | GCK 4/4885KCNH2 1830/4885NPC1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.